Presentación de PowerPoint @page { } table { border-collapse:collapse; border-spacing:0; empty-cells:show } td, th { vertical-align:top; font-size:12pt;} h1, h2, h3, h4, h5, h6 { clear:both } ol, ul { margin:0; padding:0;} li { list-style: none; margin:0; padding:0;} <!-- "li span.odfLiEnd" - IE 7 issue--> li span. { clear: both; line-height:0; width:0; height:0; margin:0; padding:0; } span.footnodeNumber { padding-right:1em; } span.annotation_style_by_filter { font-size:95%; font-family:Arial; background-color:#fff000; margin:0; border:0; padding:0; } * { margin:0;} .gr1 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr10 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .gr11 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr12 { font-size:24pt; writing-mode:lr-tb; } .gr13 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr14 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr15 { font-size:24pt; writing-mode:lr-tb; } .gr16 { font-size:24pt; writing-mode:lr-tb; } .gr17 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr18 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr19 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr2 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr20 { font-size:24pt; writing-mode:lr-tb; } .gr21 { font-size:24pt; writing-mode:lr-tb; min-height:9.857cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr22 { font-size:24pt; writing-mode:lr-tb; } .gr23 { font-size:24pt; writing-mode:lr-tb; min-height:10.624cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr24 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr25 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr26 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr27 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr28 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr3 { font-size:24pt; writing-mode:lr-tb; } .gr4 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr5 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr6 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr7 { font-size:24pt; writing-mode:lr-tb; min-height:1.272cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr8 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr9 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .P1 { font-size:14pt; } .P10 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P11 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P12 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P13 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P14 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0.176cm; line-height:100%; text-indent:0cm; } .P15 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; text-indent:0cm; } .P16 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P17 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-align:left ! important; text-indent:0cm; } .P18 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P19 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:center ! important; text-indent:0cm; } .P2 { text-align:right ! important; font-size:14pt; } .P20 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P21 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P22 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; } .P23 { margin-left:0cm; margin-right:0cm; margin-top:0.308cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P24 { margin-left:0cm; margin-right:0cm; margin-top:0.308cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P25 { margin-left:0cm; margin-right:0cm; margin-top:0.141cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P26 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P27 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P28 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P29 { margin-left:0cm; margin-right:0cm; margin-top:0.141cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P3 { text-align:center ! important; } .P30 { margin-left:0.952cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:-0.952cm; } .P31 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P32 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:0cm; } .P33 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P34 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P35 { margin-left:1.27cm; margin-right:0cm; margin-top:0cm; margin-bottom:0cm; line-height:100%; text-align:left ! important; text-indent:0cm; writing-mode:lr-tb; } .P36 { margin-left:0cm; margin-right:0cm; margin-top:0cm; margin-bottom:0cm; line-height:100%; text-align:left ! important; text-indent:0cm; writing-mode:lr-tb; } .P37 { margin-left:2.063cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:-0.793cm; } .P38 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P39 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P4 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; writing-mode:lr-tb; } .P40 { margin-left:0.952cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:-0.952cm; } .P5 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .P6 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; } .P7 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; } .P8 { writing-mode:lr-tb; } .P9 { text-align:center ! important; writing-mode:lr-tb; } .T10 { color:#ffffff; font-size:24pt; text-decoration:underline; font-weight:bold; } .T11 { color:#ffff00; font-size:14pt; font-weight:bold; } .T12 { color:#ffffff; font-size:16pt; font-weight:bold; } .T13 { color:#e5ffff; text-shadow:1pt 1pt; } .T14 { color:#e5ffff; font-size:40pt; text-shadow:1pt 1pt; } .T15 { color:#ffcc00; font-size:24pt; text-shadow:1pt 1pt; } .T16 { color:#ffff00; font-size:24pt; text-shadow:1pt 1pt; } .T17 { font-size:28pt; text-shadow:1pt 1pt; } .T18 { font-size:40pt; text-shadow:1pt 1pt; } .T19 { color:#336699; font-size:40pt; text-shadow:1pt 1pt; font-weight:bold; } .T2 { font-size:12pt; } .T20 { color:#ffff00; font-size:40pt; text-shadow:1pt 1pt; font-weight:bold; } .T21 { color:#990000; font-size:14pt; } .T22 { color:#ffffff; font-weight:bold; } .T23 { font-size:28pt; text-shadow:1pt 1pt; } .T24 { color:#ffc000; font-size:20pt; text-shadow:1pt 1pt; font-weight:bold; } .T25 { font-size:16pt; text-shadow:1pt 1pt; } .T26 { color:#ffff00; font-size:32pt; text-shadow:1pt 1pt; } .T27 { font-size:32pt; text-shadow:1pt 1pt; } .T28 { color:#ffff00; font-size:14pt; } .T29 { color:#ffffff; font-size:14pt; text-decoration:underline; } .T3 { color:#ffffff; font-size:24pt; } .T30 { color:#ff6600; font-size:14pt; font-weight:bold; } .T31 { color:#ffffff; font-size:14pt; } .T32 { color:#ffffff; } .T33 { font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T34 { font-size:18pt; text-shadow:1pt 1pt; } .T35 { color:#ffffff; font-size:16pt; } .T36 { color:#ffc000; font-size:40pt; text-shadow:1pt 1pt; } .T37 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T38 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; } .T39 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; font-weight:bold; } .T4 { text-shadow:1pt 1pt; } .T40 { color:#ffffff; font-size:28pt; text-shadow:1pt 1pt; } .T41 { color:#006fb1; } .T42 { color:#ffffff; font-style:italic; } .T43 { color:#ffff00; font-size:32pt; font-weight:bold; } .T44 { color:#ffff00; text-shadow:1pt 1pt; } .T45 { color:#ffff00; font-size:20pt; text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T46 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; } .T47 { color:#ffcc00; font-size:20pt; text-shadow:1pt 1pt; } .T48 { color:#ffff00; font-size:20pt; text-decoration:underline; font-weight:bold; } .T49 { color:#ffff00; font-size:20pt; font-weight:bold; } .T5 { font-size:24pt; text-shadow:1pt 1pt; } .T50 { color:#ffffff; font-size:20pt; text-shadow:1pt 1pt; text-decoration:underline; } .T51 { text-shadow:1pt 1pt; } .T52 { text-decoration:underline; } .T53 { color:#336699; font-size:24pt; font-weight:bold; } .T54 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:none ! important; font-weight:normal; } .T55 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:none ! important; font-weight:bold; } .T56 { color:#ffffff; font-size:16pt; font-style:normal; text-shadow:none; text-decoration:underline; font-weight:normal; } .T57 { font-size:20pt; font-weight:bold; } .T58 { font-size:20pt; } .T59 { color:#ffff00; font-size:20pt; } .T6 { font-size:20pt; text-shadow:1pt 1pt; } .T60 { color:#ffff00; font-size:20pt; text-decoration:underline; } .T61 { font-size:20pt; text-decoration:underline; } .T62 { text-shadow:1pt 1pt; text-decoration:underline; } .T63 { color:#ffff00; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T64 { font-size:24pt; text-shadow:1pt 1pt; text-decoration:underline; } .T7 { text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T8 { color:#ffffff; font-size:14pt; text-decoration:underline; font-weight:bold; } .T9 { color:#ffffff; font-size:14pt; } <!-- ODF styles with no properties representable as CSS --> .dp1 .dp2 .dp3 .dp4 .T1 { } HIPOTALAMOAREN PATOLOGIAKraneofaringioma. Haurtzaroan Supraselarra Hipertentsio endokraneala + hemianopsia bitenporala Kalzifikazioak Tratamendua: kirurgia + RT Germinoma pineala Beta-HCG Pubertasun goiztiarra Pinealoma Hipertentsio endokranealaren sindromea AkromegaliaAurpegi, esku eta oinetako hezurren gehiegizko garapena. Hipofisiak hazkuntzaren hormona gehiegi jariatzeagatik gertatzen da Irudi probakRMNErresonantzia magnetiko nuklearra (EMN)TACEskanerra GH –ren gehiegizkoaFenotipo berezia•Haurtzaroan eta nerabezaroan: gigantismoa •(garaieraren luzera) •Helduengan: akromegalia (hezurretako zabalera, oinetako eta eskuetako handitasuna, makroglosia…) Erantsitako patologiaDM. Diabetesa HTA. Hipertentsioa Ezker bentrikuloko hipertrofia (Ekokardiograma) Heste lodiaren minbizia: polipoen diagnostiko goiztiarra Loaldiko apnearen sindromea Sindrome bereziak(familiarrak)Multiple endocrine neoplasia type 1 The McCune–Albright syndrome Familial acromegaly Carney's syndrome (azalaren hiperpigmentazioa , tumore endokrinoak, aurikulako, azalaren eta mukosen mixomak MEN (Neoplasia Endocrina Multiple)1 motako aniztasun neoplasia Tumore Hipofisiko (jariatzailea ala ez) Hiperparatiroidismo primarioa Pankreako tumorea (intsulinoma/glukagonoma…) Pronostikoa DiagnostikoaGH + IGF-I maila basalak handituta daude PRL-ren neurketa (kasu mistoak) Proba (testak) dinamikoak Ahozko glukosaren gainkarga TRH testa Kaltzioaren, fosfatoren, D3-ren, PTHren eta gastrinaren neurketak (1 motako MENa aztertzeko) TratamenduaSMS analogoen tratamendua: (aukerakoa) Kirurgia (transesfenoidala/transfrontala) Sendatuz gero: IGF-I normal + GH < 1ng/ml glukosaren ahozko gainkargan (batzuen arabera: < 0.4 ng/ml) Oso helburu zorrotzak jarri dira, akromegaliaren sendatzea bermatzeko Tratamendua (II)Sendatu ezean: Tumorearen arrasto esanguratsuak gelditzen badira edota hazten bada, orduan bigarren ebakuntza aukeratzekoa da Tumoreareren arrasto txikiekin eta kendu ezinik, tratamendu farmakologikoa martxan jartzen da: SMS-en analogoak Oktreotido LAR (Sandostatin LAR) Lanreotido (Somatulina Autogela) Agonista dopaminergikoak Bromokriptina Kabergolina (gutxiegitasun mitralaren arriskua) Kinagolide RT konbentzionala/Radiokirurgia (Gamma knife) SMS analogoak (somatostatina antzekoak) EzaugarriakEfektuak Tumorearen neurriak Jario hormonala Sendatu ezean SMS analogoen kontrako eerresistenzia kasuetan: Pegvisomant : GH-ko hartzailearen antagonista bat da Adi: tumorearen neurri bilakaeraren kontrola KirurgiaEskarmentu handiko hospitaleetan (erreferentzia zentruetan) egin behar da Mikroadenoma kasuetan, sendaketa Ondorioak Diabetes zaporegabea (behin behinekoa ala behin betikoa): fase hirukoitza: Diabetes zaporegabea-SIADH (ADH sekrezio ezegokiaren sindromea -Diabetes zaporegabea Aurreko-hipofisiaren eskasia: ordezko tratamendua Meningitisa Fistula PROLAKTINOMA HiperprolaktinemiaFarmakologikoa Dopaminaren inhibitzaileak: clebopride, sulpiride, metoclopramida, haloperidol, risperidona, opiáceos, agonistas serotoninérgicos (fluoxetina, paroxetina). Klebopride, sulpiride,metoklopramida,haloperidol, risperidona, opiazeoak, agonista serotoninergikoak (fluoxetina, paroxetina)) Hipotalamoaren patologia Hipofisi zurtoinaren patologia: ebakidura, bihurdura, agenesia Hipotiroidismoa Mikro/makroprolaktinoma Akromegalia Obario polikistosia Bularreko patologia KlinikaEmakumearengan: Galaktorrea-Amenorrea sindromea Fase luteala motza Ileko irregularrak Libido gutxi Gizonarengan: Sexu ezintasuna (sexu bulkada gutxi) BietanAntzutasuna Hipotalamo-Hipofisi sintomatologia Hormonen eskasia Konpresio klinika (makroprolaktinoma) MikroprolaktinomaNeurriak < 10 mm Klinika Inpotentzia (ernaltzeko ezintasun fisiko, erabatekoa nahiz erlatiboa, baina ez da antzutasuna) (erekzioaren disfuntzio) Analitika PRL-ren eta neurrien proportzioa MakroprolaktinomaNeurriak > 10 mm Haziera extraselarra (posiblea da) Klinika Inpotentzia/amenorrea-galaktorrea Batzutan, hormonen eskasia Tokiko konpresio sintomak DiagnostikoaPRL Interferentzia farmakologikoa ekiditea Atsedenaldian aztertu (estresa baztertzeko) Lagin batzuk PRLren eta tumorearen neurrien proportzioa GH eta IGF-I Hipotiroidismoa baztertu Makroprolaktina neurtu Tratamendua (I)Agonista dopaminergikoak Bromokriptina Tolerantzia (jasamena) Ondorio kaltegarriak Digestiokoak Hipotentsio ortostatikoa Tratamendua (II)Quinagolide Eraginkortasun gutxiagoa Agonista dopaminergikoekin Hormonen normalizazioa Efektu antitumorala Tumorearen urripena Haziera ekiditea Gaztaroan mantentzea Menopausian, batzutan sendaketa. Kentzeko aukera Kirurgia Indikaziorik ez, erantzunik ezean edota intoleranzia farmakologikoan izan ezik Cirugía  no indicación salvo No respondedores o intolerancia farmacológica Treatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. Transsphenoidal surgery is also an option. Clomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement (estrogen or testosterone) may cause a decrease in efficacy of the dopamine agonist So that it must be carried out cautiously. HaurdunaldianBromokriptina kabergolina baino hobea da (segurtasun maila kabergolinarena baino handiagoa da) Mikroprolaktinoma kasuetan, agonista dopaminergikoak kendu Makroprolaktinometan, bromokriptina mantendu Kanpimetria nohizbehinka egin Cushing-en gaixotasunaGiltzurruingaineko patologian ikusiko dugu Jariatzale ez den adenoma Jariatzaleak:maiztasunaren arabera Prolaktinomak GH GH eta PRL konbinatutako adenomak TSH sortzen dutenak (arraroak) Maiztasuna%10-15 nekropsietan Maiztasuna: gliomak eta meningiomak ondoren, hirugarrenak % 25-30 hipofisiaren tumoreetakoak (agian, %10-20ª, glikoproteina inaktiboak ekoizteagatik: alfa subunitatea, LH, FSH) SintomakLokalak (neurrien arabera): makroadenometan, ikusmenaren asaldurak, kanpimetriaren akatsak, buruko mina, hipertenntsio endokraneala…. Mikroprolaktinometan: sintoma propioak (hileko irregulartasuna edota amenorrea sekundarioa (emakumengan), sexu bulkada (gizonengan) + ondoko hormona eskasiaren sintomak DiagnóstikoaJario patologikoa eta hormonen eskasia ekidin Aurre hipofisi hormona basalak Alfa Subunitatea Osmolaritatea eta elektrolitoak EMN Balorazio oftalmolgikoa Kanpimetria Ikusmenaren gaitasuna Begi-hondokoa TratamenduaKirugia transesfenoidala RT (berreritzeetan) Sehilabeteko/urteko/biurteko errebisioa Tratamendu farmakologikorik ez Berreritza: %16a 10 urteetan Bularrako edo birikako minbiziaen metastasiak Panhipopituitarismoa + DZ Dosi baxuetan emandako RT eraginkorra da Inzidentaloma hipofisarioa <10 mm. PRL neurtu + hipofuntzioaren aukera aztertu EMN hasieran errepikatu < 4mm. Hormonak normalak izanez gero, jarraipenik ez %4ª, besterik ez dira hazten %12ª txikitzen dira
